— Know what they know.
Not Investment Advice

380550.KQ

Neurophet
1W: -12.3% 1M: -26.8% 3M: -14.7% YTD: -30.3%
₩21,450.00 ($14.26)
+50.00 (+0.23%)
 
KOE · Healthcare · Medical - Healthcare Information Services · ₩247.3B
Smart Money Score
No convergence signal
Key Statistics
Market Cap₩247.3B ($164.3M)
52W Range10150-36700
Volume184,494
Avg Volume909,833
Beta0.58
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOJunkil Been
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO Date2025-07-23
Samwon Tower
Seoul
KR
82 2 6954 7971
About Neurophet

Neurophet, Inc., operates as a neuroscience company, engages in the development of medical artificial intelligence solutions in the field of brain science and diseases. The company offers Neurophet AQUA, AI-powered diagnosis assistant software for brain diseases; Neurophet SCALE PET, a software that quantitatively analyzes biomarkers targeted by a specific radiotracer using PET; Neurophet tES LAB, AI-Powered software to generate a 3D model using brain MRI and simulate electrical stimulation for treatment planning; and Neurophet innk, a non-invasive electrical stimulation device designed to aid in the functional recovery and rehabilitation of patients with brain diseases. It also provides Consulting services for design systems and quality management systems. The company was founded in 2016 and is headquartered in Seoul, South Korea.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms